EN ZH NEWS NEWARK, CA • OCTOBER 31, 2023 AceLink Announces First Patient Dosed in Phase 2 Trial of AL01211 in Fabry Disease – Plan to enroll patients across six sites throughout China – – Topline results are expected in 2H 2024 – (BUSINESS WIRE)–AceLink Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the next generation …